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Background: Genetic factors play a role in the development and severity of chronic obstructive pulmonary disease
(COPD). The pathogenesis of COPD is a multifactorial process including an inflammatory cell profile. Recent studies
revealed that single nucleotide polymorphisms (SNPs) within ADAM33 increased the susceptibility to COPD through
changing the airway inflammatory process and lung function.
Methods: In this paper, we investigated associations of four polymorphisms (T1, T2, S2 and Q-1) of ADAM33 as
well as their haplotypes with pulmonary function and airway inflammatory process in an East Asian population of
patients with COPD.
Results: We found that T1, T2 and Q-1 were significantly associated with the changes of pulmonary function and
components of cells in sputum of COPD, and T1 and Q-1 were significantly associated with cytokines and mediators
of inflammation in airway of COPD in recessive models. 10 haplotypes were significantly associated with transfer
factor of the lung for carbon monoxide in the disease state, 4 haplotypes were significantly associated with forced
expiratory volume in one second, and other haplotypes were associated with airway inflammation.
Conclusions: We confirmed for the first time that ADAM33 was involved in the pathogenesis of COPD by affecting
airway inflammation and immune response in an East Asian population. Our results made the genetic background
of COPD, a common and disabling disease, more apparent, which would supply genetic support for the study of
the mechanism, classification and treatment for this disease.
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inflammatory processBackground
Chronic obstructive pulmonary disease (COPD) is defined
as a disease state characterized by poorly reversible and
progressive airflow limitation that is usually associated
with an abnormal inflammatory response of the lung [1,2].
Nearly 90% of COPD is caused by long term cigarette
smoking, however, only 25% of chronic tobacco smokers
develop COPD [3]. Additionally, COPD tends to occur
more frequently in smokers with a family history of ob-
structive airways disorders including asthma and COPD.
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unless otherwise stated.underlying genetic factors in the development of COPD.
Variants of some genes have been investigated and identi-
fied to have close associations with COPD, such as TLR-9
[4], HHIP [5], IREB2 and CHRNA3/5 [6].
The pathophysiology of COPD is a multifactorial process
with an complex inflammatory cell profile including eosino-
phils [7], macrophages [8], neutrophils [9], and lymphocytes
[10]. The levels of some cytokines, such as interleukin(IL)-
8 [11], interleukin(IL)-6 [12], tumor necrosis factor alpha
(TNF-A) [13], and vascular endothelial growth factor
(VEGF) [14] are increased in stable COPD patients, sug-
gesting their key-roles in the pathogenesis of COPD. There-
fore, COPD develops as a result of multiple steps involving
the inflammatory cells and mediators, in which local in-
flammation in the lungs is especially important due to af-
fecting airway remodeling and parenchymal destruction.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Table 1 The clinical information of patients recruited
CASE* CONTROL
Number of patients 312 319
Age (years) 60.5 (7.8) 61.5 (8.1)
Male: Female 186:126 192:127
Pack years of smoking† 35.46 (15.9) 32.54 (12.7)
FEV1 (% predicted)‡ 52.5 (8.6) 91.5 (9.6)
FEV1/FVC (%)§ 47.5 (7.6) 90.5 (11.6)
Postbd FEV1 (% predicted)|| 58.5 (9.6) 93.5 (10.5)
Postbd FEV1/FVC (%) 49.2 (8.5) 91.5 (11.8)
TLCO (% predicted)** 63.09 (18.1) 93.21 (2.9)
GOLD status
Stage I (mild) 52 -
Stage II (moderate) 140 -
Stage III (severe) 98 -
Stage IV (very severe) 22 -
*Data are means and standard deviations (in parentheses).
†Pack year: (packs per day) × (years smoked).
‡FEV1: forced expiratory volume in first second.
§FVC: forced vital capacity.
||Postbd: post bronchodilator.
**TLCO: transfer factor of the lung for carbon monoxide.
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http://www.biomedcentral.com/1471-2466/14/173A disintegrin and metalloprotease 33 (ADAM33), a
member of the ADAM (a disintegrin and metalloprotease)
family, has been identified as an asthma susceptible gene
[15]. This finding has been further improved in many pop-
ulations, such as Indian and Chinese asthma populations
[16,17]. ADAM proteins are involved in cell adhesion, cell
fusion, cell signaling, and proteolysis [18-20]. The latter
can be illustrated by the capacity to shed cytokines, growth
factors, or their receptors from the cell surface, and the re-
modeling of extracellular matrix components. Garlisi and
colleagues demonstrated that ADAM33 is an active pro-
teinase that is able to cleave α2-macroglobulin [21], an
important member of pulmonary defense system. These
results suggested that ADAM33 is involved in the
pathogenesis of airway obstruction with affecting tissue
remodeling, a physiological process intricately related
to airway inflammation [22]. Additional studies have dem-
onstrated that single nucleotide polymorphisms (SNPs)
within ADAM33 were associated with accelerated decline
of lung function in the general population and in asthma
patients [23,24]. Recent studies further revealed that SNPs
within ADAM33 conferred susceptibility to COPD in the
general population through affecting the airway inflamma-
tory process and changing the lung function in COPD
[25-28]. Our previous study has further confirmed the as-
sociation between ADAM33 gene polymorphisms and
COPD in the Northeastern Chinese Han population [29].
The aim of this study is to investigate the associations of
SNPs in ADAM33 with the severity of the pulmonary
function and airway inflammation in patients with COPD.
Methods
312 patients with stable COPD were recruited for this
study. The criteria of the recruitment have been described
in detail previously [29], and are shown in Table 1. In brief,
all patients had irreversible airflow limitation and chronic
respiratory symptoms, and were current or ex-smokers
with at least 20 pack-years of smoking. Patients did not
use a course of inhaled or oral corticosteroids within
3 months, or maintenance treatment with these drugs
within 6 months. None of the patients had a history of
asthma. Patients with acute exacerbations two months
preceding study assessment were also excluded. Disease
severity was classified according to the criteria of Global
Initiative for Chronic Obstructive Lung Disease (GOLD)
[1]. Approval from the Ethics Committee of Harbin Med-
ical University was obtained before initiating the study.
COPD patients were informed of the study protocol and
provided written consent.
DNA was extracted from peripheral blood of both
COPD patients and control samples, and genotyping was
performed as described previously [29] using polymerase
chain reaction-restriction fragment length polymorphism
(PCR-RFLP) analysis. Based on our previous study [29], thefour SNPs in ADAM33 have been genotyped: Q-1(C/T),
S2 (G/C), T1 (Met-Thr), T2 (Pro-Ser) and the primers used
are listed in Table 2.
Sputum induction and processing
Sputum samples were obtained in the stable clinical state
of COPD patients, at least two months after any exacerba-
tion. Following the established standards for inducing
sputum [30], patients inhaled 200 ug of salbutamol and
afterwards 3% saline from an ultrasonic nebulizer for three
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volume in one second (FEV1) occurred. If this occurred,
consecutive sputum inductions were performed using
0.9% saline. Samples produced after the three inhalation
periods were processed separately and pooled values were
derived by weighted averaging [31].
All adequate plugs of sputum were selected. After incu-
bation with Sputolysin TM, Giemsa-stained cytospins
were prepared. Non-squamous cells were counted by two
independent observers, and the average of the values was
taken for analysis. The levels of IL-6, IL-8, TNF-a and
VEGF in sputum supernatants were determined in ad-
equately diluted samples by ELISA (U.S. TPI kit).
Lung function measurement
Pulmonary function testing of both COPD patients and
control samples was evaluated on a Jaeger Transfer screen
II (Erich Jaeger GmbH, Würzburg, Germany) and in-
cluded: total lung volume; FEV1; vital capacity (VC); forced
vital capacity (FVC); peak expiratory flow (PEF); and trans-
fer factor of the lung for carbon monoxide (TLCO). Evalu-
ation of the pulmonary function is relied on standards
established by the Chinese Medical Association. The mean
standard residual values of FEV1 are normally distributed
and independent of height, age and gender.
Data analysis
We first tested whether SNPs were in Hardy–Weinberg
equilibrium. Logistic regression analyses were then per-
formed to test the association between each SNP with
COPD case/control status, and linear regression analyses
were performed to assess the relationships between SNPs
and quantitative phenotypes, i.e. pulmonary function mea-
surements (percent predicted (pp) FEV1, ppFVC, and
ppTLCO), inflammatory cells (eosinophils, lymphocyte,
macrophage, neutrophil and sputum) and cytokines in spu-
tum (IL-8, IL-6, TNFA and VEGF). Both regression ana-
lyses were adjusted based on the age, sex and pack-years
smoked. Three genetic models were used: dominate model
(homozygotes and heterozygotes for the minor allele being
compared as a group with homozygotes for the major
allele), codominant model (three genotype groups per
SNP separately) and recessive model (homozygotes and
heterozygotes for the major allele being compared as a
group with homozygotes for the minor allele). Statistical
analysis was performed using the PLINK software (version
1.07, http://pngu.mgh.harvard.edu/purcell/plink/) [32], and
haplotype analysis was also conducted using the same soft-
ware. P < 0.05 was considered statistically significant.
Results
All genotype frequencies were consistent with Hardy-
Weinberg equilibrium (p > 0.01). T1, T2 and Q-1 were sig-
nificantly associated with COPD (p < 0.00004) adjusted forsex, age and pack-years smoked. In addition to controlling
the p-value by the Benjamini-Hochberg method, we
performed an alternative adjustment for multiple compari-
sons using a permutation-based approach. After this
adjustment, these three SNPs still show significant associa-
tions with COPD (adjusted p < 0.00005).
Results of multiple regression analyses assuming a dom-
inant model and codominant model are shown in the
Additional file 1. Multiple regression analyses assuming a
recessive model are presented below.
Association of ADAM33 SNPs with inflammatory cells in
sputum
The analysis was conducted among cases only. The results
showed that T1 was significantly associated with the per-
centage of lymphocyte (p = 0.03), Q-1 was associated with
the percentage of macrophage (p = 0.02), and T2 was asso-
ciated with total cell count in sputum (p = 0.03) under a re-
cessive genetic model. T2 and T1 showed a trend toward
association for the percentage of lymphocyte (p = 0.06) and
total cell count in sputum (p = 0.07), respectively (Figure 1).
However, no other significant association between these
SNPs and other type of inflammatory cells was observed.
Association of ADAM33 SNPs with cytokines in sputum
There were no significant associations between IL-6 and
these SNPs in recessive models. In contrast, the T1 SNP
showed a significant association with IL-8 (p < 0.01) in
subjects with COPD. The Q-1 SNP was associated with
IL-8, TNF-A and VEGF (p < 0.01) (Figure 2). T2 and S2
were not associated with cytokines in sputum.
Association ofADAM33 SNPs with pulmonary function
The significant pulmonary functions were identified in the
patients with any SNPs in comparison to the control sam-
ples. T2 and T1 were significantly associated with ppFEV1
(Figure 3), ppFEV1/FVC (Figure 4) and ppTLCO (Figure 5)
within COPD cases in recessive models (p < 0.05). The
Q-1 SNP was also significantly associated with ppTLCO
(p < 0.01). When examining control samples only, there
was no significant association between these SNPs and
any of the measures of lung function.
Haplotype association analysis
The haplotype associations with pulmonary function or
inflammatory processes were investigated. 8 haplotypes
on T2, T1, S2 and Q-1 were significantly different be-
tween cases and controls in either the crude analysis or
the analysis adjusting for age, gender and smoking.
Other 3 haplotypes were significantly different in the
analysis adjusting for age, gender and smoking (Table 3).
We investigated associations of haplotypes with cell
count and cytokines in sputum with patients of COPD.
GAGG, AGGG, AACG, AGCG and GGCA were found to
Figure 1 Association of ADAM33 SNPs with the inflammatory cells in sputum under a recessive genetic model. A: the percentage of
lymphocyte; B: the percentage of macrophage; C: the total cell amount in sputum).
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GAGG was significantly associated with the percentage
of lymphocyte, GACG was significantly associated with
TNF-A, GACA, AAGA and GAGA were significantly as-
sociated with VEGF, and GAGG, AACG and AGCG was
significantly associated with IL-8 in the analysis adjusting
for age, gender and smoking (Table 4).
We investigated associations of haplotypes with pul-
monary function in COPD and controls in the analysis ad-
justed for age, gender and smoking. Only GAGA was
significantly associated with ppFEV1 in the normal state.
10 haplotypes were significantly associated with ppTLCO
in the disease state, 4 haplotypes (AAGG, GGCA, GGGA
and AACG) were significantly associated with ppFEV1
and ppFEV1/FVC, while only GGGG was significantly as-
sociated with ppFEV1. AAGG, GGCA and GGGA were
significantly associated with pulmonary functions (FEV1,
FEV1/FVC and TLCO) (Table 5).
9 different haplotypes (except GACA and GACG)
were significantly associated with TLCO in either thecrude analysis or the analysis adjusting for age, gender
and smoking.
Discussion
To our knowledge, this is the first study to show signifi-
cant association between four polymorphisms (T1, T2,
S2 and Q-1) of ADAM33 as well as their haplotypes and
pulmonary function and airway inflammation of patients
with COPD in an East Asian population. We first found
that T1, T2 and Q-1 were significantly associated with
COPD, while Figarsk et al. revealed that S1, S2, T2
and Q-1 were significantly associated with COPD in
Vlagtwedde/Vlaardingen cohort [25]. Since no associ-
ation was found between S1 and COPD in our previous
study in a northeastern Chinese population [29], we did
not include S1 in this study. We also found that T1, T2
and Q-1 were significantly associated with pulmonary
function and components of cells in sputum of COPD,
and T1 and Q-1 were significantly associated with cyto-
kines and mediators of inflammation in airway of COPD
Figure 2 Association of ADAM33 SNPs with cytokines in sputum under a recessive genetic model. A: IL-8; B: TNF-A; C: VEGF.
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involved in the pathogenesis of COPD and multiple SNPs
loci of interaction could promote the progress of COPD.
ADAM33 is a member of the zinc-dependent metallo-
proteinase ADAM superfamily, which regulate their own
function and a wide range of other proteins through
proteolytic cleavage [33]. ADAM33 has multiple domains
including prodomain, catalytic, metalloprotease, disintegrin
(binds integrins), cysteine-rich/epidermal growth factor
(cell-cell contact), transmembrane, and cytoplasmic do-
mains, and has multiple splice forms containing various
combinations of these domains. ADAM33 is predominantly
expressed in airway structural cells, including airway epi-
thelium, airway smooth muscle (ASM), myofibroblasts,
and fibroblasts, and is thought to have a wide spectrum
of functions, such as protease-dependent and independent
mechanisms. ADAMs cleaves proteins from the cell surface
and might facilitate release of cytokines and growth factors.
The pathogenesis of COPD involves the recruitment and
regulation of neutrophils, macrophages, and lymphocytes
to the lung, as well as the induction of imbalance betweenproteinases and antiproteinases, all of which result in lung
parenchymal destruction and airway remodeling. Based on
the expression profile and functions, ADAM33 is involved
in pathogenesis of COPD. Our study showed that the SNP
T1 is significantly associated with macrophage and T2 is
significantly associated with total cells in sputum of patients
with COPD, Q-1 was significantly associated with IL-8,
TNF-A and VEGF in sputum of COPD. Therefore, like
other ADAMs, ADAM33 can promote the release of cyto-
kines and growth factors, lead to inflammatory cells infiltra-
tion in the airway. In addition, soluble ADAM33 has been
implicated in angiogenesis [22] and new vessels, and may
promote inflammatory cells and cytokines or growth factors
in the airway. Although not as well studied, there is evi-
dence that the vascular areas of the airway is significantly
increased in COPD and are related to the degree of airflow
obstruction [34]. In this current study, our results showed
that T1 and Q-1 affected lymphocyte and macrophage, im-
plying that ADAM33 might affect the immune response of
the airways and further promote the formation of COPD.
Some studies have also found the association between
Figure 3 Association of ADAM33 SNPs with ppFEV1 under a recessive genetic model.
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COPD. For example, Winkler et al. found that the products
of activated macrophages have also been implicated in in-
flammation and tissue destruction, including in COPD [35].
Domagala-Kulawik et al. showed in their study that macro-
phages were involved in the inflammatory process caused
by smoking in COPD and were associated with severe air-
flow limitation [36].Figure 4 Association of ADAM33 SNPs with ppFEV1/FVC under a receIn the airway of patients with COPD, the inflammation
limits the airflow and further causes a loss of lung func-
tion of COPD. It is known that pulmonary function de-
cline is a prominent characteristic for the development
of COPD and cardiovascular disease [37]. Our data con-
firmed that T1 and T2 were significantly associated with
decreased FEV1 and FEV1/FVC, T2, T1 and Q-1 were
significantly associated with decreased TLCO. The studyssive genetic model.
Figure 5 Association of ADAM33 SNPs with ppTLCO under a recessive genetic model.
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results in asthmatic patients [38]. It is important to note
that ADAM33 SNPs have also shown associations with
excess FEV1 decline in general population samples. The
main SNPs identified included Q-1, S1, S2 with excess
decline of 23.6 to 9.6 mL/y. S1 and S2 were associated
with COPD in this population, reflecting the potentialTable 3 Association of haplotypes with COPD in both the
crude and the adjusted analysis
P-value
T2 T1 S2 Q-1 Unadjusted Adjusted*
G G G G 3.734e-011 1.1e-013
G G C G 6.32e-009 1.72e-011
A A G A 3.514e-006 3.76e-007
A A G G 5.16e-006 8.81e-007
G A G A 0.003103 0.0016
A A C A 0.004037 0.000244
A G G A 0.04011 0.00803
G A C A 0.01269 0.00398
G G C A – 0.00712
G G G A – 0.0131
G A C G – 0.026
G A G G –
A A C G –
A G G G –
A G C G –
*The analysis adjusted for age, gender and smoking.role of ADAM33 in airway remodeling in multiple re-
spiratory diseases. Emphysema is another main patho-
logical condition for COPD [39]. It’s worth noting that,
in comparison to other studies, our study also identified
the relationship between SNP and TLCO of COPD since
TLCO associated with the severity of emphysema. We
found that T2, T1 and Q-1 were associated with de-
creased TLCO of COPD, suggesting that the ADAM33
also play a role in the pathogenesis of emphysema. An im-
balance of endogenous proteinases and antiproteinases is
considered to be a major mechanism for emphysematous
lung destruction. In this context, matrix metalloproteinase
have aroused interest due to their capability of inducing
emphysema by proteolysis of lung parenchyma. Similar to
matrix metalloproteinase, the ADAM family possesses
proteolytic and adhesive activity. As a member of this gene
family, any alterations of ADAM33 may affect the regula-
tion of cell-cell and cell-matrix adhesion and the extent of
extracellular matrix degradation. Therefore, it is conceiv-
able that mutations in ADAM33 might promote emphyse-
matous changes, a main phenotype or pathologic change
of COPD.
We found that T1, T2 and Q-1 were significantly associated
with COPD. The SNP Q-1 is located in the intron immedi-
ately before exon 16, which contains an epidermal growth
factor (EGF) domain [40]. EGFR signaling regulates matrix
metalloprotease, which mediates epithelial-mesenchymal
interactions during lung morphogenesis [41]. The mice
lacking the EGF receptor (EGFR) demonstrate abnormal
branching and poor alveolarization. ADAM33 is closely
related to matrix metalloprotease, but may bind EGF
Table 4 Association of haplotypes with inflammatory cells and cytokines in sputum in the adjusted analysis
P-value
T2 T1 S2 Q-1 Sputum Neutrophil Macrophage Lymphocyte Eosinophils TNF-A VEGF IL-6 IL-8
G A G G 0.00207 0.0239 7.07e-006
A A C G 0.00598 0.0322
A G G G 0.00823
A G C G 0.0146 0.0435
G G C A 0.0349
G A C G 0.0338
G A C A 0.00419
A A G A 0.0188
G A G A 0.0361
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spliced out, giving rise to the β -variant of ADAM33. This
variant was found in 30% of ADAM33 mRNA transcripts
in pulmonary fibroblasts [42]. The intronic Q-1 SNP has
been identified to influence the splicing of the β–variant
[43], and disturb the maturation of ADAM33. Because the
EGF domain is incomplete, it has been suggested that the
β –variant prevents maturation of ADAM33 and may
exert a dominant-negative effect on its protease activity
[44]. Subsequent effects on protease activity may result in
a defect in tissue repair after inflammation-induced dam-
age. This may lead to progressive destruction of alveolar
tissue and thereby enhance accelerated decline in lung
function of COPD.
The T1 and T2 SNPs are located in the exon 19 (which
includes an SH3 domain and a phosphorylation site) of
the cytoplasmic tail, which may affect signaling [29]. T1,
T2 are in the domain Reprolysin family propeptide, which
interacts with 5 domains, including Thrombospondin,
C-type lection and ADAM-TS Spacer 1. ThrombospondinTable 5 Association of haplotypes with pulmonary function in
T2 T1 S2 Q-1 Percent-predicted FEV1 FEV1/FVC Percent-p
TLC
Disease
G G G G 0.0247 – 1.04e
G G C G – – 0.000
A A G A – – 0.000
A A G G 0.00176 0.000154 1.67e
A A C A – – 0.000
G A G A – – –
G G C A 0.000234 0.000272 1.22e
A G G A – – 0.03
G G G A 8.68e-005 0.00209 6.98e
G A G G – – 0.003
A A C G 0.0154 0.0465 0.001 is an antiangiogenic factor, which can inhibit the prolif-
eration and migration of endothelial cells. Angiogenesis is
a key process in the evolution and maintenance of psoria-
sis and other chronic inflammatory diseases, such as in-
flammatory bowel disease, chronic obstructive pulmonary
disease, and rheumatoid arthritis [45]. Proteins that con-
tain C-type lectin domains have a diverse range of func-
tions including cell-cell adhesion, immune response to
pathogens and apoptosis. Apoptosis has been recognized
to play an important role in clinical and experimental
models of lung diseases [46]. Recently many reports have
been published highlighting the presence of apoptosis in
human COPD lungs and its role in the pathogenesis of
emphysema [47]. ADAM-TS Spacer1 represents the
Spacer-1 region from the ADAM-TS family of metallopro-
teinase and ADAM-TS family has some lung-related bio-
logical actions [48].
In this current study, we also analyzed associations be-
tween haplotypes of four polymorphisms (T1, T2, S2 and




Percent-predicted FEV1 FEV1/FVC Percent-predicted
TLCO
Normal
-005 – – –
205 – – –
368 – – –
-007 – – –
224 – – –
0.005447 – –
-005 – – –
92 – – –
-016 – – –
19 – – –
14 – – –
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http://www.biomedcentral.com/1471-2466/14/173inflammation of patients with COPD. GAGG, AGGG,
AACG, AGCG and GGCA were found to be significantly
associated with total cell count in sputum: GAGG was sig-
nificantly associated with increase lymphocyte count;
GACG was significantly associated with increased level of
TNF-A; GACA, AAGA and GAGA were significantly as-
sociated with VEGF; and GAGG, AACG and AGCG was
significantly associated with IL-8 in the analysis adjusted
for age, gender and smoking. These results demonstrated
that multiple SNPs could work together to promote airway
inflammation of patients with COPD. It is worth noting
that 10 haplotypes were found to be significantly associ-
ated with ppTLCO in the disease state, 5 of these haplo-
types (AAGG, GGCA, GGGA, AACG and GGGG) were
significantly associated with ppFEV1, and 4 haplotypes
(AAGG, GGCA, GGGA and AACG) were significantly as-
sociated with ppFEV1/FVC. These results indicated that
although there were no common associations between sin-
gle SNP and inflammatory cells in sputum, haplotypes of
these SNPs were found to be associated with the quantita-
tive traits. COPD high-risk groups could be screened out
using these haplotypes of ADAM33 in the future, though
much effort should be put into this clinical field.
We focused on the association of four polymorphisms
(T1, T2, S2 and Q-1) of ADAM33 as well as their haplo-
types with pulmonary function and airway inflammation
of patients with COPD, thus, no sputum cells were ob-
tained from control samples. More comprehensive data
should be obtained to reveal the mechanism of COPD in
further study.Conclusions
In this paper, we confirmed for the first time that ADAM33
was involved in the pathogenesis of COPD in an East Asian
population by affecting airway inflammation and immune
response. Our results made the genetic background of
COPD, a common and disabling disease, more apparent,
which would supply genetic support for the study of mech-
anism, classification and treatment for this disease.Additional file
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